Acadian Asset Management
XBIO icon

Acadian Asset Management’s Xenetic Biosciences XBIO Stock Holding History

Acadian Asset Management’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-151
Closed -$35K – 2065
2019
Q1 		$35K Buy
151
+65
+76% +$15.9K ﹤0.01% 1742
2018
Q4 		$16K Hold
86
– – ﹤0.01% 1578
2018
Q3 		$30K Buy
+86
New +$33.6K ﹤0.01% 1460

Other funds holding XBIO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Acadian Asset Management's XBIO Position: Q2 2019 in Review

Acadian Asset Management sold out of Xenetic Biosciences (XBIO) in Q2 2019, closing a stake of 151 shares — an estimated $35K sold.

Acadian Asset Management first reported a position in XBIO in Q3 2018 and held it in 3 quarters. The position peaked at $35K in Q1 2019. 7 funds tracked by Wall St. Rank hold XBIO as of Q2 2019.

  • Acadian Asset Management reported no remaining Xenetic Biosciences position as of Q2 2019 after selling out during the quarter.
  • Acadian Asset Management sold 151 Xenetic Biosciences shares in Q2 2019, an estimated $35K.
  • Acadian Asset Management first reported a position in Xenetic Biosciences in Q3 2018 and held it in 3 quarters.
  • Acadian Asset Management's Xenetic Biosciences position peaked at $35K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2019.

Based on Acadian Asset Management's 13F filing for Q2 2019, filed 8 Aug 2019.